Feature Story (2013) – Army’s Lariam Expert Funded by Drug Maker

A PROFESSOR who has advised the Department of Defence on its practice of prescribing the Lariam anti-malarial drug to Irish troops has previously received research funding from Roche, its manufacturer.

Patricia Schlagenhauf, a pharmacist and editor of the Journal of Travel Medicine, states in her online CV that she has been the “malaria prevention adviser” to the “Irish armed forces” since 2010.


Roche-funded mefloquine proponent, Patricia Schlagenhauf

The Department of Defence confirmed that she contributed to its working-group report on the use of Lariam that Alan Shatter, the justice minister, has declined to publish on the basis of legal privilege.

The state is facing 24 High Court actions from current and former soldiers who claim they became ill after being prescribed Lariam.

An updated warning published by Roche last July said the drug … read more

Mark Tighe, Army’s Lariam expert funded by drug-maker, The Sunday Times, 27 October 2013.

Clare Daly questions Simon Coveney in Irish Parliament, 8 October 2015

Related Stories

Mark Tighe, First pay-out over drug blamed for soliders’ suicides, The Times, 14 October 2015.

Shane Phelan, Anti-malarial drug to be withdrawn from Irish market, Independent.ie, 13 October 2015.

Michael O’Regan, Concerns raised about soldiers taking Lariam, The Irish Times, 9 October 2015.

Shane Phelan, Expert says former soldier’s suicidal thoughts linked to antimalarial drug, Independent.ie, 16 April 2015.

Shane Phelan, Defence legal bill will hit €5m as Lariam cases begin to mountIndependent.ie, 21 August 2014.

Tim O’Brien, Kenny defends use of anti-malaria drug Lariam despite concerns, Irish Times, 14 June 2014.

David Ralph, Lariam: Why is drug linked to suicide still being given to soldiers?, Irish Examiner, 30 January 2014.

Finally Garland, Report on controversial anti-malarial drug to remain secret, The Irish Times, 16 October 2013.


About IMVAlliance.org

An international network of military veterans, families and friends affected by the health impacts of the neurotoxic antimalarial drug, mefloquine.
This entry was posted in Advocacy, Clinical Drug Trials, Media, Research and tagged , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s